Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab …
WEB6 days ago · NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15. Cachexia is a common, life-threatening wasting condition that can ...
Drug breakthrough provides new hope for cancer patients with cachexia
WEB56 minutes ago · University of Rochester Medical Center Sep 19 2024. Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common ...
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab
WEB5 days ago · About the Phase 2 Trial in Cancer Cachexia The primary objective of the Phase 2 study (NCT05546476) is to assess the effect of ponsegromab on body weight in patients with cancer (non-small cell ...
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab …
WEB5 days ago · NEW YORK, September 14, 2024--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its ...
New therapy shows promise in improving appetite, quality of life …
WEB4 days ago · The Pfizer-sponsored study enrolled 187 participants across the world — including 10 from Oregon Health & Science University, the most of any clinical trial site in North America — in a study to better understand if the therapy ponsegromab could help participants increase body weight and appetite, and help with other cachexia symptoms.
Pfizer's cancer cachexia drug shows positive midstage trial results
WEB6 days ago · Pfizer ’s experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial, the drugmaker said ...
Ponsegromab for the Treatment of Cancer Cachexia
WEB5 days ago · Methods. In this phase 2, randomized, double-blind, 12-week trial, we assigned patients with cancer cachexia and an elevated serum GDF-15 level (≥1500 pg per milliliter) in a 1:1:1:1 ratio to ...
New Pathways to Cachexia Treatment: Focusing on Patient ... - Pfizer
WEBJul 10, 2020 · Pfizer’s flagship cachexia program focuses in on growth differentiation factor-15 (GDF-15), a cytokine, or cellular signaling protein, that is linked to appetite and energy regulation. Patients with late-stage illnesses, particularly cancer, have elevated levels of this signaling protein.
WEBPreliminary phase 1 data suggest that suppression of GDF-15 may lead to improvement in cachexia-related symptom burden. Ponsegromab is a potent and selective humanized monoclonal antibody that inhibits GDF-15-mediated signaling.
Phase 2 study to assess the efficacy, safety, and tolerability of the ...
WEBMay 31, 2023 · Ponsegromab is a potent and selective humanized monoclonal antibody that inhibits GDF-15-mediated signaling. The primary objective of this study (NCT05546476) is to assess the effect of ponsegromab on body weight in patients with cancer, cachexia, and elevated circulating GDF-15 concentrations.
- Some results have been removed